Imagine opening Excel and no longer needing to wrestle with complex formulas or spend hours manually analyzing data. What if you could simply type a question, like “What are the top-performing ...

A new COPILOT function in Excel lets you use AI in a formula. The new skill is now available to Microsoft 365 insiders. Reduces some of the complexity involved in creating formulas. Get more in-depth ...

Copilot is on the way to Microsoft Excel. Or rather, more Copilot is being packed into the popular spreadsheet program. A new COPILOT function is rolling out now to users in the Beta Channel and ...

Have you ever wished Excel could just understand what you mean without endless tinkering with formulas or wrestling with messy data? That wish is no longer a distant dream. Microsoft’s new Excel AI ...

Marvell Technologies stock tumbled on Friday after a disappointing earnings report. The company reported light data-center revenue, and its sales forecast missed estimates. Analysts are worried that ...

The Dow industrials set a new intraday high Friday, fueled by Warren Buffett's vote of confidence in UnitedHealth, but fell short of settling at their first record close of 2025. An after-hours filing ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An update from Hyperscale Data ( (GPUS)) ...

Bloomberg just reported — literal seconds ago — that the Trump Administration is discussing taking a 10% stake in Intel (Nasdaq: INTC). No details at present and the stock hasn’t had time to react ...

U.S. stock futures are lower after another strong day on Wall Street as rate cut hopes gained steam, but inflation data and weekly jobless claims due before the bell could swing sentiment. July's ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. BofA Securities analyst Steve Byrne removed his sell ...

Viking Therapeutics has reported phase 2 data on its oral obesity drug candidate, linking the peptide to weight loss of up to 12.2% after 13 weeks. But, with 38% of patients discontinuing treatment at ...